Connect with us

Hi, what are you looking for?

Deluxe Investment GroupDeluxe Investment Group

Stock

Elon Musk’s Neuralink raises $650 million in fresh capital

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS

Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!



    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Latest News

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Latest News

    In the final three weeks of the presidential race, former president Donald Trump and his advisers have attacked one particular foe more than three...

    Latest News

    “And there’s very few states that benefit like you do from fracking. I mean, you have 500,000 jobs.” — Former president Donald Trump, remarks...

    Latest News

    A former deputy Palm Beach County sheriff who fled to Moscow and became one of the Kremlin’s most prolific propagandists is working directly with...

    Disclaimer: Deluxeinvestmentgroup.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 deluxeinvestmentgroup.com